The German laboratory CureVac announced Tuesday that it was putting an end to the development of its first anticovid vaccine, which initially generated a lot of hope but whose results ended up being disappointing, and that it was concentrating on another more promising immunizer.
This firm, specialized in messenger RNA technology, will "focus on the development of a second generation covid-19 vaccine", in which it works with the British GSK, and therefore will "remove" your current draft of the European Medicines Agency (EMA) continuous review procedures.
This "ends" also to the pre-agreement of 405 million doses agreed with the European Union (EU), reported the laboratory.
"The global fight against covid-19 continues and we are determined to make a decisive contribution to it with a safe and effective vaccine"Franz-Werner Haas, director of CureVac, assured in a statement.
Clinical trials showed an efficacy of 48% in this initial vaccine from the German laboratory, a much lower percentage than the drugs developed by Pfizer / BioNTech and Moderna.
CureVac and GSK want to launch in the "next months" a clinical study on this second-generation vaccine, which does take into account the new variants of the virus that have appeared, to be approved in 2022.
"Congratulations on the fact that CureVac is focusing on the promising second generation vaccine", christened CV2CoV, on which the first studies show a "net improvement" about the first, said Rino Rappuoli, GSK’s chief scientific officer.